The difference in tirzepatide and semaglutide comes down to seven key areas. These are: how they work, what they're approved for, how they're dosed, how much weight loss they produce, how they compare on tolerability, their cardiovascular evidence base, and which patients are best suited for each. Understanding each distinction provides the foundation for an informed, individualized conversation with a prescribing provider about which option is most appropriate for a specific patient's clinical profile and treatment goals.

Fact 1: How They Work Is Fundamentally Different

Semaglutide is a GLP-1 receptor agonist. It activates one receptor. GLP-1 receptor activation slows gastric emptying, suppresses appetite, and produces glucose-dependent insulin secretion. These effects reduce food intake and support weight loss.

Tirzepatide is a dual GIP and GLP-1 receptor agonist. It activates two receptors simultaneously. The GIP receptor adds complementary effects on energy metabolism and fat storage. It also appears to have antiemetic effects that partially offset the nausea from GLP-1 receptor activation. These combined effects explain why tirzepatide produces more weight loss and fewer GI-related discontinuations at maximum doses, even though semaglutide's GLP-1 mechanism is well-established and effective.

Fact 2: FDA Approval Status and Indications Differ

Semaglutide has three FDA-approved formulations. Ozempic (injectable) was approved for type 2 diabetes in December 2017. Rybelsus (oral tablet, 7 or 14 mg) was approved for type 2 diabetes in September 2019, making it the only oral GLP-1 receptor agonist currently available. Wegovy (injectable 2.4 mg) was approved for chronic weight management in June 2021. Semaglutide (as Wegovy) also received an indication for reducing major adverse cardiovascular events in adults with obesity and cardiovascular disease in 2024, further extending its clinical applications.

Tirzepatide has two FDA-approved formulations. Mounjaro (injectable) was approved for type 2 diabetes in May 2022. Zepbound (injectable) was approved for chronic weight management in November 2023. Tirzepatide does not yet have an approved cardiovascular outcomes indication.

Fact 3: Dosing Schedules Are Similar but Not Identical

Both drugs are administered as weekly subcutaneous injections for their weight management indications. Semaglutide (Wegovy) starts at 0.25 mg weekly and escalates over 16 weeks to the target dose of 2.4 mg weekly. Tirzepatide (Zepbound) starts at 2.5 mg weekly and escalates every four weeks up to the target maintenance dose of 5, 10, or 15 mg weekly. The tirzepatide titration schedule allows for flexible maintenance dosing across three dose levels rather than a single fixed target dose, which gives more flexibility in dose adjustment for tolerability.

Fact 4: Tirzepatide Produces More Weight Loss

The evidence at this point is clear on relative efficacy. In SURMOUNT-1, tirzepatide produced weight losses of 16.0%, 21.4%, and 22.5% at 5, 10, and 15 mg over 72 weeks in adults with obesity without diabetes. STEP-1 showed semaglutide producing 14.9% over 68 weeks in a comparable population.

The first direct head-to-head trial, SURMOUNT-5, published in NEJM in July 2025, confirmed the advantage in a controlled comparison. Tirzepatide produced 20.2% mean weight loss versus 13.7% with semaglutide at maximum tolerated doses over 72 weeks. Tirzepatide users were more likely to achieve every benchmark tested: 10%, 15%, 20%, and 25% weight reduction.

Fact 5: Tirzepatide Has Better GI Tolerability at Maximum Doses

Both drugs produce GI side effects from GLP-1 receptor activation. Nausea, vomiting, diarrhea, and constipation are the most common, particularly during dose escalation. Both use gradual titration to minimize these effects.

The difference appears in discontinuation rates at maximum doses. In SURMOUNT-5, GI-related treatment discontinuation was 2.7% with tirzepatide versus 5.6% with semaglutide. The GIP receptor's antiemetic contribution appears to explain this advantage. Preclinical research from the University of Pennsylvania published in September 2025 confirmed that GIP receptor agonism counteracts GLP-1-driven nausea in animal models.

Fact 6: Semaglutide Has More Established Cardiovascular Outcomes Data

This is the area where semaglutide maintains a meaningful clinical advantage. The SELECT trial, published in NEJM in 2023, demonstrated that semaglutide reduced major adverse cardiovascular events by 20% in adults with obesity and established cardiovascular disease without diabetes. This is direct, randomized outcomes evidence.

Tirzepatide has promising cardiovascular data but not an equivalent outcomes trial yet. A post-hoc analysis of SURMOUNT-5 published in September 2025 estimated tirzepatide was associated with a greater predicted 10-year cardiovascular risk reduction than semaglutide (2.4% versus 1.4% absolute reduction) based on cardiometabolic marker changes. This is not equivalent to observed event reduction from a dedicated trial. For patients with significant cardiovascular disease, semaglutide's SELECT evidence is a relevant clinical distinction.

Fact 7: Patient Candidacy Differs Based on Priorities

For most patients with obesity and no significant cardiovascular disease, current evidence favors tirzepatide for maximum weight loss with better GI tolerability. The SURMOUNT-5 head-to-head results support this preference for the weight loss indication. Patients who have previously tried semaglutide and experienced intolerable GI side effects are a specific group for whom tirzepatide's lower discontinuation rate may be especially relevant.

For patients with established cardiovascular disease where reducing cardiovascular events is a primary clinical goal, semaglutide's SELECT trial provides directly relevant outcomes evidence that tirzepatide currently cannot match. Semaglutide has also been available for significantly longer, meaning that its prescribers and patients have accumulated more real-world experience managing its use across a wider variety of clinical scenarios. Patients who have achieved good results on semaglutide and are not experiencing significant GI issues have little reason to switch based on currently available evidence alone. Patients who want maximum weight loss and can tolerate either drug are the population for whom SURMOUNT-5's findings are most directly relevant. For them, tirzepatide is the evidence-supported first choice.

What the Two Drugs Share

Both also share several important characteristics despite their differences. Neither drug is a short-term intervention. Weight regain occurs after stopping either medication. Tirzepatide's SURMOUNT-4 trial showed approximately two-thirds of lost weight regained within 52 weeks of stopping. Semaglutide's STEP-4 trial showed a similar regain pattern. Ongoing use is required to maintain results, which has implications for cost, access, and long-term planning. Cardiometabolic markers including blood pressure, HbA1c, fasting insulin, triglycerides, and HDL cholesterol improve with both drugs beyond weight loss alone. Both carry the same FDA class-level black box warning regarding thyroid C-cell tumors based on rodent data. Both represent the most effective pharmaceutical weight loss interventions ever available without surgery.

THRYVE Wellness Medical's Functional Medicine program uses comprehensive Biomarker Testing to evaluate the full metabolic, hormonal, and cardiovascular profile before recommending either medication. Treatment decisions consider weight loss goals, cardiovascular history, GI tolerance, concurrent medications, and cost or insurance access alongside the published clinical evidence from SURMOUNT-5 and SELECT.

Frequently Asked Questions

What is the main difference between tirzepatide and semaglutide?
Tirzepatide activates both GIP and GLP-1 receptors; semaglutide activates only the GLP-1 receptor. This dual mechanism produces greater weight loss and better GI tolerability with tirzepatide at maximum doses, while semaglutide has more established cardiovascular outcomes data.

Is tirzepatide stronger than semaglutide?
In terms of weight loss, yes. SURMOUNT-5 showed 20.2% versus 13.7% weight loss at 72 weeks. For cardiovascular outcomes, semaglutide currently has the stronger evidence base.

Which drug has fewer side effects?
Both share GI side effects, but tirzepatide showed lower GI-related discontinuation in SURMOUNT-5 (2.7% vs 5.6%). Both carry the same class-level thyroid warning.

Are tirzepatide and semaglutide approved for the same things?
No. Both are approved for obesity and type 2 diabetes, but semaglutide also has an approved indication for reducing cardiovascular events. Tirzepatide does not yet have this indication.

Which is more expensive?
Pricing varies by insurance coverage, location, and assistance programs. Both medications are expensive without coverage. Cost and access are practical considerations alongside clinical factors in medication selection.

Key Takeaways

Tirzepatide's dual GIP and GLP-1 mechanism produces more weight loss than semaglutide's single GLP-1 mechanism: 20.2% versus 13.7% in the SURMOUNT-5 head-to-head trial. Tirzepatide's dual GIP and GLP-1 mechanism produces more weight loss than semaglutide's single GLP-1 mechanism. GI tolerability at maximum doses favors tirzepatide (2.7% vs 5.6% discontinuation). Semaglutide has a dedicated cardiovascular outcomes trial (SELECT) that tirzepatide currently lacks. Semaglutide has been available longer and has three approved formulations including an oral option. Both drugs require continued use to maintain weight loss results. Patient candidacy depends on weight loss goals, cardiovascular history, GI tolerance history, and cost and insurance access.

The Bottom Line

The difference in tirzepatide and semaglutide is meaningful across all seven dimensions covered here. No single factor determines which is more appropriate for any given patient. Tirzepatide's greater weight loss and better GI tolerability favor it for most patients focused primarily on weight management and who lack significant cardiovascular comorbidities. Semaglutide's cardiovascular outcomes evidence and longer market history favor it for specific patient profiles, particularly those with established cardiovascular disease. Both represent a genuine and substantial advance in the pharmacological management of obesity, and both require a thorough clinical evaluation before initiation and continued monitoring throughout use.